CD274 and metastatic melanoma: On 09/15/2022, the European Medicines Agency (EMA) issued marketing authorization for relatlimab plus nivolumab throughout the European Union for patients 12 years of age and older with unresectable or metastatic melanoma with programmed cell death ligand 1 (PD-L1) expression less than 1% [31].